To investigate the possible clinical interaction between the platelet function regulator @entity17732 (SP) and the oral anticoagulant @entity11271 (AC), 22 in- @entity1 of either sex were included in a single blind within- @entity1 trial vs. placebo. After one week of stabilizing treatment with AC alone the @entity1 were randomly allocated to two sequences (11 @entity1 each), either SP + AC for weeks 2--3 followed by placebo + AC for weeks 4--5, or the reverse sequence, i.e. placebo + AC followed by SP + AC for the same periods. 17 @entity1 completed the full five weeks. Four dropped out during SP treatment, all but one following some form of @entity548 episode. One @entity1 dropped out for the same reason during placebo. Apart from the @entity548 episodes, no other undesirable effects were recorded. The daily dose of SP was always 800 mg. A statistically highly significant interaction (p less than 0.01) between SP and AC was found. The addition of SP to AC led to a drop in mean prothrombin time and rendered necessary a consequent reduction (of about 20%) in mean AC dosage. It is concluded that when initiating and withdrawing treatment with SP in a @entity1 receiving AC, the prothrombin time should be checked daily for a few days to adapt (reduce) the dosage of AC to the change in prothrombin time induced by SP.

[The effect of XXXX on the coagulation-inhibiting action of @entity11271 ].

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity17732 :: ('MESH:D013442', 'Chemical') :: ['sulphinpyrazone'] @entity11271 :: ('MESH:D000074', 'Chemical') :: ['acenocoumarol'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']
@entity17732 :: (MESH:D013442,Chemical) :: ['sulfinpyrazone']
